HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Addy, C. Articles by Wagner, J. Search for Related Content PubMed PubMed Citation Articles by Addy, C. Articles by Wagner, J. Social Bookmarking                         What's this?

Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, in Healthy Male Volunteers

From Merck Research Laboratories, Boston, Massachusetts (Dr Addy); Merck Research Laboratories, Rahway, New Jersey (Dr Rothenberg, Dr Yuan, Dr Maes, Dr Dunbar, Ms Cote, Ms Rosko, Dr Gottesdiener, Dr Stoch, Dr Wagner); Merck Research Laboratories, West Point, Pennsylvania (Dr S. Li, Dr Majumdar, Dr Agrawal, Mr H. Li, Dr Zhong); MSD (Europe), Brussels, Belgium (Dr Van Dyck, Dr De Lepeleire); Center for Clinical Pharmacology, University Hospital, Leuven, Belgium (Dr de Hoon, Dr Van Hecken, Dr Depré); and SGS Life Science Services, Antwerp, Belgium (Dr Knops). Paul Rothenberg's current affiliation is Johnson & Johnson, Raritan, New Jersey. Jinyu Yuan's current affiliation is Pfizer, New York, NY. Annemie Knops' current affiliation is CM Limburg, Hasselt, Belgium.

Taranabant is a cannabinoid-1 receptor inverse agonist for the treatment of obesity. This study evaluated the safety, pharmacokinetics, and pharmacodynamics of taranabant (5, 7.5, 10, or 25 mg once daily for 14 days) in 60 healthy male subjects. Taranabant was rapidly absorbed, with a median t_max of 1.0 to 2.0 hours and a t_1/2 of approximately 74 to 104 hours. Moderate accumulation was observed in C_max (1.18- to 1.40-fold) and AUC_{0-24 h} (1.5- to 1.8-fold) over 14 days for the 5-, 7.5-, and 10-mg doses, with an accumulation half-life ranging from 15 to 21 hours. Steady state was reached after 13 days. After multiple-dose administration, plasma AUC_{0-24 h} and C_max of taranabant increased dose proportionally (5-10 mg) and increased somewhat less than dose proportionally for 25 mg. Taranabant was generally well tolerated up to doses of 10 mg and exhibited multiple-dose pharmacokinetics consistent with once-daily dosing.

Key Words: MK-0364 • taranabant • canabinoid-1 receptor inverse agonist • obesity • appetite • satiety

Address for reprints: Carol Addy, MD, MMSc, Director, Clinical Pharmacology, Merck Research Laboratories, 33 Avenue Louis Pasteur, HB3-429, Boston, MA 02115; e-mail: carol_addy{at}merck.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Addy, P. Jumes, K. Rosko, S. Li, H. Li, A. Maes, A. O. Johnson-Levonas, J. Chodakewitz, S. A. Stoch, and J. A. Wagner Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid-1 Receptor (CB1R) Inverse Agonist J. Clin. Pharmacol., October 1, 2009; 49(10): 1228 - 1238. [Abstract] [Full Text] [PDF]

				J. I. Schwartz, S. Dunbar, J. Yuan, S. Li, D. L. Miller, K. Rosko, A. O. Johnson-Levonas, K. C. Lasseter, and J. A. Wagner Influence of Taranabant, an Orally Active, Highly Selective, Potent Cannabinoid-1 Receptor (CB1R) Inverse Agonist, on Ethinyl Estradiol and Norelgestromin Plasma Pharmacokinetics J. Clin. Pharmacol., January 1, 2009; 49(1): 72 - 79. [Abstract] [Full Text] [PDF]